Invex Therapeutics Ltd
IXC
Company Profile
Business description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Contact
c/- Automic Group
Level 5, 191 St Georges Terrace
PerthWA6000
AUST: +61 1300288664
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.10 | 29.10 | 0.32% |
| CAC 40 | 8,350.87 | 150.08 | 1.83% |
| DAX 40 | 24,635.30 | 425.59 | 1.76% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,471.72 | 167.84 | 1.63% |
| HKSE | 24,718.10 | 468.81 | 1.93% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 66,020.04 | 1,802.77 | 2.81% |
| NZX 50 Index | 13,393.87 | 191.71 | 1.45% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,804.00 | 30.50 | 0.35% |
| SSE Composite Index | 4,031.51 | 44.50 | 1.12% |